FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma

Autor: Elie W. Akl, Elio Adib, Talal El‐Zarif, Toni K. Choueiri, Charlene Mantia, Rohit Jain, William Paul Skelton, Praful Ravi, Dory Freeman, David J. Kwiatkowski, Catherine Curran, Amin Nassar, Guru Sonpavde
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: BJUI Compass, Vol 3, Iss 2, Pp 169-172 (2022)
BJUI Compass
ISSN: 2688-4526
Popis: Enfortumab Vedotin (EV) is approved for metastatic urothelial carcinoma (mUC) progressing post-platinum and PD1/L1 inhibitor therapy. Erdafitinib is approved for post-platinum mUC with activating somatic genomic alterations (GAs) in FGFR2/3. Information on the activity of EV in mUC with FGFR2/3 alterations will facilitate optimal clinical management. In this multi-center, retrospective analysis, we assessed the overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) to EV in mUC patients with and without FGFR2/3 GAs including mutations and fusions. Multivariable cox-regression and logistic regression analyses with 2-tailed p-values were used to evaluate the association of GAs with outcomes. A majority of the evaluable 60 patients were male (44/60, 78%), exhibited ECOG performance score 0–1 (53/60, 88.3%) and had a median age of 70.5 (range 48 – 88) years when starting EV. GAs in FGFR2/3 did not influence the ORR (p=0.32), OS (p=0.79) or PFS (p = 0.32) with EV. In conclusion, FGFR2/3 GAs did not appear to compromise major outcomes with EV in mUC. Larger studies are required to further evaluate the impact of FGFR2/3 GAs on the activity of EV and the optimal sequencing of EV and erdafitinib in mUC.
Databáze: OpenAIRE
Externí odkaz: